IPP Bureau

Mumbai FC Football players encourage cancer survivors at Nanavati Max Super Speciality Hospital
Mumbai FC Football players encourage cancer survivors at Nanavati Max Super Speciality Hospital

By IPP Bureau - February 04, 2023

The players and management of Mumbai City FC presented patients with exclusive gifts, symbolizing support and appreciation for their fight against cancer

GMM Pfaudler posts Q3 FY23 consolidated profit at Rs. 18.67 Cr
GMM Pfaudler posts Q3 FY23 consolidated profit at Rs. 18.67 Cr

By IPP Bureau - February 03, 2023

The company has reported total income of Rs. 781.40 crores during the period ended December 31, 2022

Theramex select CARA Life Sciences Platform to consolidate and digitise Regulatory Processes
Theramex select CARA Life Sciences Platform to consolidate and digitise Regulatory Processes

By IPP Bureau - February 03, 2023

Theramex were searching for a platform to digitise the manual processes across their R&D landscape

Apollo Hospitals partners with MediSage
Apollo Hospitals partners with MediSage

By IPP Bureau - February 03, 2023

Experts’ conclave to pave holistic approach to cancer management

Dabur India consolidated Q3FY23 PAT lower at Rs. 475.94 Cr
Dabur India consolidated Q3FY23 PAT lower at Rs. 475.94 Cr

By IPP Bureau - February 03, 2023

The company has posted net profit of Rs. 475.94 crores for the period ended December 31, 2022

Jubilant Ingrevia posts Q3FY23 consolidated PAT at Rs. 91.53 Cr
Jubilant Ingrevia posts Q3FY23 consolidated PAT at Rs. 91.53 Cr

By IPP Bureau - February 02, 2023

The company has reported total income of Rs. 1165.31 crores during the period ended December 31, 2022

Hester Biosciences Q3 FY23 consolidated net profit up at Rs. 11.18 Cr
Hester Biosciences Q3 FY23 consolidated net profit up at Rs. 11.18 Cr

By IPP Bureau - February 02, 2023

The company has reported total income of Rs. 79.33 crores during the period ended December 31, 2022

Jubilant’s Radiopharma business receives NDA approval for Technetium Mertiatide Injection
Jubilant’s Radiopharma business receives NDA approval for Technetium Mertiatide Injection

By IPP Bureau - February 02, 2023

The Tc 99m Mertiatide Injection is used in the diagnosis of congenital and acquired renal abnormalities

Balaxi Pharmaceuticals revenue up 40.3%
Balaxi Pharmaceuticals revenue up 40.3%

By IPP Bureau - February 02, 2023

During the quarter, foreign exchange fluctuations had an impact of Rs. 4.56 crore Q3 FY23 Profit After Tax after considering exchange rate fluctuations stood at Rs. 8.2 crore

Budget 2023-24: Industry welcomes focus on medical research and pharma innovation
Budget 2023-24: Industry welcomes focus on medical research and pharma innovation

By IPP Bureau - February 02, 2023

It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047

Lupin receives tentative approval from USFDA for DETAF tablets
Lupin receives tentative approval from USFDA for DETAF tablets

By IPP Bureau - February 01, 2023

DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries

Cloud adoption helping healthcare providers drive higher levels of patient care
Cloud adoption helping healthcare providers drive higher levels of patient care

By IPP Bureau - February 01, 2023

91% of cloud leaders expect their cloud capabilities to be largely centralized within the next 2 years and 64% of cloud leaders have realized cybersecurity cost savings by migrating to cloud

Sun Pharma Q3 FY23 Gross Sales up 13.1%; Net profit up 5.2%
Sun Pharma Q3 FY23 Gross Sales up 13.1%; Net profit up 5.2%

By IPP Bureau - February 01, 2023

India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year

Economic Survey 2022-23: Industry sector witness growth of 4.1%
Economic Survey 2022-23: Industry sector witness growth of 4.1%

By IPP Bureau - February 01, 2023

The Survey highlighted that Indian pharmaceutical exports achieved a healthy growth of 24 per cent in FY21 and expressed hope that India’s domestic pharmaceutical market is estimated to grow to US $65 billion by 2024 from estimated US $41 billion in 2021

CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

By IPP Bureau - January 31, 2023

CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%

Latest Stories

Interviews

Packaging